Loading
Inflammation from infection, injury or surgery can wake dormant cancer cells. Interleukin-1 beta drives that awakening in mouse models of breast cancer, and a cardiovascular trial of the interleukin-1 beta blocker canakinumab saw fewer lung cancers, so blocking it early might keep dormant cells asleep.
Interleukin-1 beta from the bone marrow niche drives the exit of breast cancer cells from dormancy and metastatic outgrowth in mouse models, and a large cardiovascular trial of canakinumab reported an unexpected reduction in lung cancer incidence and mortality. Later lung cancer treatment trials of canakinumab in advanced disease were negative, which is consistent with awakening being an early, not late, event.
Shares Late recurrence, Metastasis is understood least and studied last, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), HR-positive / HER2-negative breast cancer.
Shares Late recurrence, Dormant cells and minimal residual disease.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.